[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n RY0/Le4vfEE00JAMzAa8OcWm+sVsK1bOuEEnqgXTeiXixfrL8pXox6RE4LBVSTb8\n Ip74dmFEXlZKH7CxULHpaQ==\n\n', u'0000950133-04-003440.txt : 20040908\n', u'0000950133-04-003440.hdr.sgml : 20040908\n', u'20040908162652\nACCESSION NUMBER:\t\t0000950133-04-003440\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t3\nCONFORMED PERIOD OF REPORT:\t20040908\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040908\nDATE AS OF CHANGE:\t\t20040908\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tMARTEK BIOSCIENCES CORP\n\t\tCENTRAL INDEX KEY:\t\t\t0000892025\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]\n\t\tIRS NUMBER:\t\t\t\t521399362\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1031\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-22354\n\t\tFILM NUMBER:\t\t041020949\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t6480 DOBBIN RD\n\t\tCITY:\t\t\tCOLUMBIA\n\t\tSTATE:\t\t\tMD\n\t\tZIP:\t\t\t21045\n\t\tBUSINESS PHONE:\t\t4107400081\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t6480 DOBBIN RD\n\t\tCITY:\t\t\tCOLUMBIA\n\t\tSTATE:\t\t\tMD\n\t\tZIP:\t\t\t21045\n', u'\n', u'\n', u'8-K\n', u'1\n', u'w01887e8vk.htm\n', u'FORM 8-K\n', u'\n', u'e8vk', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'SECURITIES AND EXCHANGE COMMISSION\n\n\n\n', u'Washington, D.C. 20549\n\n\n\n', u'FORM 8-K', u'\n', u'CURRENT REPORT', u'\n', u'Pursuant to Section\xa013 or 15(d)', u'\nof the Securities Exchange Act of 1934\n\n\n\n', u'Date of Report (Date of earliest event reported): September\xa08, 2004\n\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'MARTEK BIOSCIENCES CORPORATION', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'(Exact name of registrant as specified in its charter)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Delaware', u'\n', u'\xa0', u'\n', u'0-22354', u'\n', u'\xa0', u'\n', u'52-1399362', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'(State or other jurisdiction of', u'\nincorporation or organization)\xa0\n', u'\n', u'\xa0', u'\n', u'(Commission File', u'\nNumber)\n', u'\n', u'\xa0', u'\n', u'(I.R.S. Employer', u'\nIdentification No.)', u'\n', u'\n', u'\xa0', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'6480 Dobbin Road, Columbia Maryland', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'21045', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'(Address of principal executive offices)\n', u'\n', u'\xa0', u'\n', u'\xa0\n', u'\n', u'\xa0', u'\n', u'(Zip Code)', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Registrant\x92s telephone number, including area code: (410)\xa0740-0081\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'(Former name or former address, if changed since last report)\xa0', u'\n', u'\n', u'\xa0', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0Check the appropriate box below if the Form 8-K filing is intended to\nsimultaneously satisfy the filing obligation of the registrant under any of the\nfollowing provisions:\n\n\n', u'\xa0\xa0\xa0\xa0\xa0', u'o', u'\xa0 Written communications pursuant to Rule\xa0425 under the\nSecurities Act (17 CFR 230.425)\n\n\n', u'\xa0\xa0\xa0\xa0\xa0', u'o', u'\xa0 Soliciting material pursuant to Rule\xa014a-12 under the\nExchange Act (17 CFR 240.14a-12)\n\n\n', u'\xa0\xa0\xa0\xa0\xa0', u'o', u'\xa0 Pre-commencement communications pursuant to Rule\xa014d-2(b)\nunder the Exchange Act (17 CFR 240.14d-2(b))\n\n\n', u'\xa0\xa0\xa0\xa0\xa0', u'o', u'\xa0 Pre-commencement communications pursuant to Rule\xa013e-4(c)\nunder the Exchange Act (17 CFR 240.13e-4(c))\n\n\n', u'-1-\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'INFORMATION TO BE INCLUDED IN THE REPORT', u'\n', u'Item\xa02.02. Results of Operations and Financial Condition.', u'\n', u'\xa0\xa0\xa0\xa0\xa0On September\xa08, 2004, Martek issued a press release announcing its\nfinancial results for the fiscal quarter ended July\xa031, 2004. A copy of\nMartek\x92s press release is furnished as Exhibit\xa099.1 to this press release.\n\n\n', u'\xa0\xa0\xa0\xa0\xa0The information in this Current Report on Form 8-K, including Exhibit\xa0No.\n99.1 hereto, shall not be deemed \x93filed\x94 for purposes of Section\xa018 of the\nSecurities Exchange Act of 1934, as amended, or otherwise subject to liability\nof that section. The information in this Current Report shall not be\nincorporated by reference into any filing or other document pursuant to the\nSecurities Act of 1933, as amended, except as shall be expressly set forth by\nspecific reference in such filing or document.\n\n\n', u'Item\xa09.01. Financial Statements and Exhibits.', u'\n', u'(c)\xa0Exhibits', u'\n', u'The following is furnished as an Exhibit to this Current Report on Form 8-K.\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\xa0', u'\n', u'Description of Exhibit', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Press Release dated September\xa08, 2004 issued by Martek Biosciences\nCorporation (Furnished pursuant to Item\xa02.02).', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'-2-\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'SIGNATURES', u'\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Martek Biosciences Corporation', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Date: September 8, 2004', u'\n', u'\xa0', u'\n', u'\nBy:\n', u'\n', u'\xa0', u'\n', u'/s/ George P. Barker', u'\n', u'\nGeorge P. Barker', u'\nSenior Vice President, General', u'\nCounsel and Secretary', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'-3-\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'2\n', u'w01887exv99w1.htm\n', u'EXHIBIT 99.1\n', u'\n', u'exv99w1', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 99.1\n\n', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'FOR IMMEDIATE RELEASE', u'\n\xa0\n', u'\n', u'\xa0', u'\n', u'Contact:', u'\n', u'\xa0', u'\n\xa0\n', u'\n', u'\xa0', u'\n', u'Pete Buzy', u'\nChief Financial Officer', u'\n(410)\xa0740-0081', u'\n', u'\n', u'\xa0', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'MARTEK ANNOUNCES THIRD QUARTER FINANCIAL RESULTS', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'REVENUES OVER $47 MILLION; EARNINGS OF $5 MILLION', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'COLUMBIA, MD \x96 September\xa08, 2004: Martek Biosciences Corporation (NASDAQ:MATK)\ntoday announced its financial results for the third quarter and nine months\nended July\xa031, 2004. For the third quarter of 2004 (3rd Qtr 04), revenues of\n$47.3\xa0million were achieved, up from $29.1\xa0million for the 3rd Qtr 03, and for\nthe nine months ended July\xa031, 2004 (04 YTD), revenues of $124.8\xa0million were\nachieved, up from $76.1\xa0million for 03 YTD. For the 3rd Qtr 04, Martek earned\nnet income of $5.0\xa0million, or $0.16 per diluted share, compared to net income\nof $4.6\xa0million or $0.16 per diluted share in the 3rd Qtr 03. For 04 YTD,\nMartek earned net income of $11.8\xa0million, or $0.38 per diluted share, compared\nto net income of $9.8\xa0million or $0.37 per diluted share for 03 YTD.\n\n\n', u'\x93Martek has been able to overcome production problems created by the fire at\nDSM\x92s U.S. facility and still achieve a 63% quarterly revenue growth. New\nproduction capacity coming on-line as well as increased efficiencies and\neconomies of scale should allow rapid growth to continue with increasing gross\nprofit margins in the coming quarters. \x93 stated Henry \x93Pete\x94 Linsert, Jr.,\nChief Executive Officer of Martek.\n\n\n\n', u'3rd Qtr Consolidated Financial Results', u'\n', u'Total revenues for the 3rd Qtr 04 were $47.3\xa0million, an increase of $18.2\nmillion or 63% over the 3rd Qtr 03. A significant portion of this increase is\ndue to higher sales of nutritional products to the Company\x92s infant formula\nlicensees (For a history of the Company\x92s nutritional product sales by quarter\nsee the chart at ', u'http://www.martekbio.com/images/corporatePages/VU79P.gif', u').\nApproximately 90% of Martek\x92s 3rd Qtr 04 nutritional product sales were\ngenerated from sales of docosahexaenoic acid (DHA)\xa0and arachidonic acid (ARA)\nto four of the Company\x92s infant formula licensees: Mead Johnson, Wyeth, Abbott\nLaboratories and Nestle. Supplemented term infant formulas manufactured by\nthree of these companies were introduced in the U.S. in 2002, and Nestle\nlaunched a supplemented formula in the U.S. in 2003. Also included in Martek\x92s\n3rd quarter revenues were $3.3\xa0million related to contract manufacturing\nrevenues generated by the former FermPro business in Kingstree, SC, which was\nacquired in September\xa02003. Significant revenue growth is projected by the\nCompany for fiscal years 2005 and 2006. In order to maximize the profitability\nof these revenues and ensure a sufficient infrastructure exists to support this\ngrowth, Martek has recently expanded both the research and development and\nselling, general and administrative areas within the Company. See below for\nadditional discussion.\n\n\n', u'Consistent with the prior two quarters of fiscal 2004, during the 3rd quarter,\nthe Company satisfied as much customer demand as possible, while, at times,\nsacrificing cost efficiencies. As such, gross profit margin on total revenues\ndecreased to 38% during the 3rd Qtr 04, from 42% for the 3rd Qtr 03, but\nimproved from the gross profit margin of 35% realized in the 2nd Qtr 04. The\ndecrease from 3rd Qtr 03 resulted from the Company\x92s continued use of air\nfreight in connection with ARA shipments from Europe and internal production\ninefficiencies in connection with the commencement of DHA manufacturing at the\nKingstree plant. The gross profit margin for the current quarter was also\nimpacted by an increase in the Company\x92s overall cost of ARA due to the decline\nin the U.S. dollar against the euro; however, such impact was largely offset by\nthe benefits of certain DHA production improvements recently developed and an\ninsurance receipt by Martek of approximately $1\xa0million associated with the\nfire incident at DSM. We expect our gross profit margins in the 4th Qtr 04 to\ncontinue to reflect the benefits of the newly implemented production methods\nand expect the impact of the negative factors noted above to be greatly\nmitigated by the end of Martek\x92s fiscal year. Gross profit margin for the 3rd\nQtr 04 compared to the 3rd Qtr 03 also includes the impact of $3.3\xa0million of\nlower margin contract manufacturing revenues related to the former FermPro\nbusiness.\n\n\n', u'Research and development expenses increased by $1.5\xa0million or 42% in the 3rd\nQtr 04 compared to the 3rd Qtr 03. The increase is primarily the result of the\nadditional resources directed toward our continuing efforts to lower our DHA\nproduction cost by increasing our fermentation production yields and developing\nnew downstream processing techniques. In addition,\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'costs were incurred in\nconnection with the development of DHA products for the food and beverage\nindustry and exploration of new DHA applications as well as in the long-term\ndevelopment of plant-based DHA under the collaboration agreement with\nSemBioSys.\n\n\n', u'Selling, general and administrative expenses increased by $2.8\xa0million or 67%\nduring the 3rd Qtr 04 over the 3rd Qtr 03. Of this increase, approximately\n$800,000 relates to our Kingstree, SC plant acquired in September\xa02003, for\nwhich an administrative infrastructure has been added to support the new\nfacility and its expansion. The remaining increase is primarily due to\nadditional personnel and insurance costs required to accelerate and manage the\nCompany\x92s overall growth. Specifically, the Company has increased staffing in\nits business development, food and beverage sales and marketing and finance\ndepartments.\n\n\n', u'Other operating expenses totaled $1.6\xa0million and $200,000 in the 3rd Qtr 04\nand 3rd Qtr 03, respectively. These expenditures related primarily to\nproduction start-up costs associated with the expansion at our Kingstree, SC\nfacility and qualifications of certain third-party manufacturers as well as\nexpenses related to the Winchester wastewater treatment matter. We anticipate\ncontinuing to incur these types of expenses for the remainder of fiscal 2004.\n\n\n', u'Net income of $5.0\xa0million, or $0.16 per share on a diluted basis, was realized\nin the 3rd Qtr 04, compared to net income of $4.6\xa0million, or $0.16 per share\non a diluted basis for the 3rd Qtr 03.\n\n\n\n', u'Year-to-date Consolidated Financial Results', u'\n', u'Total revenues for 04 YTD were $124.8\xa0million, an increase of $48.7\xa0million or\n64% over 03 YTD, due primarily to higher sales of nutritional products to the\nCompany\x92s infant formula licensees. Gross profit margin decreased to 37% for 04\nYTD, from 41% for 03 YTD, primarily due to higher freight costs and unfavorable\nexchange rate fluctuations, both related to our ARA costs from DSM. Research\nand development expenses increased by $4.0\xa0million or 42% in 04 YTD compared to\n03 YTD due to the commencement of various development projects. Selling,\ngeneral and administrative expenses increased by $7.4\xa0million or 66% in 04 YTD\nover 03 YTD due primarily to increased personnel and insurance costs required\nto support the Company\x92s growth as well as the addition of our new Kingstree,\nSC facility. Other operating expenses, as described above, of $2.7\xa0million and\n$1.3\xa0million, were incurred in 04 YTD and 03 YTD, respectively. Net income of\n$11.8\xa0million, or $0.38 per diluted share was realized for 04 YTD, compared to\nnet income of $9.8\xa0million, or $0.37 per diluted share for 03 YTD.\n\n\n', u'The Company used cash flow from operations of $2.0\xa0million for 04 YTD. This use\nof cash was primarily the result of the continued buildup of DHA inventory. Due\nto a shortage of ARA, this additional DHA inventory could not be blended with\nARA for sales to infant formula manufacturers during the 3rd Qtr 04, but now\nwell positions Martek to respond to the expected demand for DHA-only\napplications such as the pregnancy and lactation market and provides the\nCompany with certain protection from future unanticipated DHA inventory\nshortfalls. Capital expenditures for 04 YTD were $153.1\xa0million, the majority\nof which were related to the expansion of the newly acquired Kingstree, SC\nfacility to increase output of the Company\x92s nutritional oils. The Company\ngenerated cash flow from financing activities of $103\xa0million primarily due to\nborrowings under the Company\x92s revolving credit facility and proceeds from the\nexercise of stock options and the issuance of common stock. At the end of the\nquarter, Martek had approximately $37.7\xa0million in cash, cash equivalents and\nshort-term investments, a decrease of $59.2\xa0million from October\xa031, 2003. In\norder to meet its capital needs, the Company may raise capital in the public or\nprivate markets, in the form of debt or equity, in the coming quarters.\n\n\n', u'As noted above, the Company continues to add manufacturing capacity and\ngenerally expand its business to meet market demand for its products. In order\nto support this expansion, Martek has increased overall staffing levels. As of\nJuly\xa031, 2004, the Company employed 518 full-time employees, of which 153 have\nbeen hired during the first nine months of fiscal 2004, including 126 whose\nfocus relates to production or research and development activities.\n\n\n\n', u'Recent Highlights', u'\n', u'Recent events impacting Martek include:', u'\n', u'\n', u'\n', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'Production and Supply of Nutritional Oils ', u'\x96 Since fiscal 2003, the\ndemand for our nutritional oils for use in infant formula products has\nsignificantly exceeded production capacity. These shortfalls have\nresulted from an acceleration of such demand over what our customers had\nprojected coupled with a shortage of ARA production capacity from DSM\nthat began in the first quarter of fiscal 2004. Martek has historically\nproduced the DHA component at its Winchester, KY facility and purchased\nthe ARA component from DSM at its Capua, Italy plant. The Company is in\nthe process of a significant production expansion including additional\nARA production from DSM. Our expansion initiatives include the\nfollowing:', u'\n', u'\n', u'\n', u'2\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xba', u'\n', u'\xa0', u'\n', u'Expansion of Kingstree production facility ', u'\x96 During the 3rd\nQtr 04, Martek continued its extensive expansion at its Kingstree,\nSC location for the fermentation and processing of the Company\x92s\nnutritional oils. The overall expansion is expected to cost $170 -\n$180\xa0million when complete. Certain components of the initial phase\nof the expansion commenced commercial operation during the 3rd Qtr\n04 with other components of this phase, including the fermentation\narea, expected to commence commercial operation and generate\nproducts available for sale in the 4th Qtr 04. Upon completion of\nthe second expansion phase in 2nd Qtr 05, Martek\x92s DHA production\ncapacity should triple over current levels.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xba', u'\n', u'\xa0', u'\n', u'Production at DSM\x92s Belvidere Facility ', u'\x96 In May\xa02004, a fire\noccurred at the Belvidere, New Jersey manufacturing plant of DSM\ncausing a temporary shutdown of the ARA production line. In June\n2004, DSM restarted the production line at the Belvidere facility.\nSince that time, Belvidere has continued to increase its monthly\noutput of ARA. It is anticipated that by the end of fiscal 2004,\nMartek will be receiving approximately 40% of its ARA from DSM\x92s\nBelvidere facility with that percentage expected to grow in the\nfuture.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'New toddler \x93follow-on\x94 product ', u'\x96 Two infant\n      formula manufacturers\nhave launched a new toddler product supplemented with Martek\x92s DHA and\nARA. The new lines are formulated to meet the nutritional needs of\nchildren from nine to twenty-four months of age, and are the first of\ntheir kind in the U.S. to be fortified with DHA and ARA.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'New Vice President of Marketing \x97 ', u'In August\xa02004, David Ross joined\nMartek as Vice President of Marketing and Sales. Prior to joining\nMartek, Mr.\xa0Ross spent 25\xa0years at Merck & Co., most recently serving as\nVice President, Marketing in the Merck Vaccine Division since 1999. In\nthis position, he was responsible for the worldwide marketing and\ndevelopment of portfolio vaccine products which generated annual\nrevenues totaling approximately $1\xa0billion. Mr.\xa0Ross received his M.S.\nin Industrial Administration from Purdue University and his B.S. degree\nin Microbiology and Public Health from Michigan State University.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\x95', u'\n', u'\xa0', u'\n', u'DHA Alzheimer\x92s Animal Study \x96 ', u'In September\xa02004, the results of an\nanimal study conducted by the UCLA School of Medicine of the effects of\nMartek\x92s DHA on the advancement of Alzheimer\x92s disease in laboratory\nmice were published in the journal Neuron. The study found that a diet\nrich in DHA significantly lessened the memory loss and cell damage\ncaused by Alzheimer\x92s disease in laboratory mice. These findings add to\nthe evidence that DHA may play a role in countering the progression of\nAlzheimer\x92s disease in humans.', u'\n', u'\n', u'\n', u'\n', u'Investor Conference Call Webcast', u'\n', u'Investors may listen to Martek\x92s senior management discuss the Company\x92s\nquarterly earnings and other current business issues on Wednesday, September\xa08,\n2004 at 4:45 p.m. EDT by accessing Martek\x92s website at ', u'www.martekbio.com', u',\nselecting the \x93Investors\x94 tab, choosing \x93Live Webcast\x94 and following the\nrelated instructions. The webcast will be available for replay through the\nclose of business on September\xa022, 2004.\n\n\n\n', u'General', u'\n', u'Sections of this release contain forward-looking statements concerning, among\nother things: (1)\xa0expectations regarding future revenue growth, product\nintroductions, growth in nutritional product sales, production expansion,\nmargin and productivity improvements, applications and potential\ncollaborations; (2)\xa0expectations regarding sales to infant formula licensees;\n(3)\xa0expectations regarding future efficiencies in manufacturing processes and\nthe costs of production of nutritional oils and purchase of third-party\nmanufactured oils; and (4)\xa0expectations regarding production capacity and the\ncost of expansion. These statements are based upon numerous assumptions which\nMartek cannot control and involve risks and uncertainties that could cause\nactual results to differ. These statements should be understood in light of the\nrisk factors set forth above and in the Company\x92s filings with the Securities\nand Exchange Commission, including, but not limited to our Form 10-K for the\nfiscal year ended October\xa031, 2003 and other filed reports on Form 10-Q and\nForm 8-K.\n\n\n\n', u'About Martek', u'\n', u'Martek Biosciences Corporation develops, manufactures and sells products from\nmicroalgae. The Company\x92s products include: (1)\xa0specialty, nutritional oils for\ninfant formula that aid in the development of the eyes and central nervous\nsystem in newborns; (2)\xa0nutritional supplements and food ingredients that may\nplay a beneficial role in promoting mental and cardiovascular health throughout\nlife; and (3)\xa0new, powerful fluorescent markers for diagnostics, rapid\nminiaturized screening, and gene and protein detection.\n\n\n\n', u'3\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'MARTEK BIOSCIENCES CORPORATION', u'\n', u'\nSummary Consolidated Financial Information', u'\n(Unaudited \x97 $ in thousands, except share and per share data)\n\n\n\n', u'Consolidated Statements of Income Data', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Three months ended July 31,', u'\n', u'\xa0', u'\n', u'Nine months ended July 31,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Revenues:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Product sales:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Nutritional product sales', u'\n', u'\xa0', u'\n', u'$', u'\n', u'43,396', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'28,748', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'112,331', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'75,183', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Fluorescent detection product sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'561', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'292', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,809', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'754', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total product sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'43,957', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,040', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'114,140', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'75,937', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Contract manufacturing sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,273', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,350', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other revenue', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'107', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'75', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'342', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'170', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total revenues', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'47,337', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,115', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'124,832', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'76,107', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Costs and expenses:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of product sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'26,264', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,017', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'70,042', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'45,001', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of contract manufacturing sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,912', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,549', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,932', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,482', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'13,660', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,628', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Selling, general and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,872', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,115', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,750', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,316', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Restructuring reversal', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(250', u'\n', u')', u'\n', u'\n', u'\n', u'Other operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,587', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'247', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,691', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,313', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total costs and expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'42,567', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,861', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'113,692', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'67,008', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income from operations', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,770', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,254', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,140', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,099', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other income, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'241', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'349', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'651', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'656', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,011', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,603', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,791', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,755', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income tax expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'30', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'5,011', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,603', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'11,761', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'9,755', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic earnings per share', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.17', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.17', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.41', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.39', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted earnings per share', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.16', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.16', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.38', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.37', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Shares used in computing basic earnings per share', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,270,301', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'27,050,781', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'28,936,660', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,793,415', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Shares used in computing diluted earnings per share', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31,168,113', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,399,615', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31,105,821', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'26,544,481', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Consolidated Balance Sheet Data', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'July 31,', u'\n', u'\xa0', u'\n', u'October 31,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(Audited)', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Assets:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash, cash equivalents and short-term investments', u'\n', u'\xa0', u'\n', u'$', u'\n', u'37,723', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'96,971', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'61,751', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'41,373', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property, plant and equipment, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'236,916', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'88,314', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Goodwill and other long-term assets, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'82,259', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'68,865', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'$', u'\n', u'418,649', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'295,523', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Liabilities and stockholders\x92 equity:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current liabilities', u'\n', u'\xa0', u'\n', u'$', u'\n', u'36,659', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'32,126', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Non-current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'97,845', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19,433', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'284,145', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'243,964', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'$', u'\n', u'418,649', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'295,523', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'4\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'Consolidated Cash Flow Data', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Nine Months Ended July 31,', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Operating activities:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'11,761', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'9,755', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Non-cash items', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,908', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,971', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Changes in operating assets and liabilities, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(19,654', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2,401', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash (used in)/ provided by operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,985', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,325', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Investing activities:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Purchase of property, plant and equipment', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(153,093', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(20,459', u'\n', u')', u'\n', u'\n', u'\n', u'Cash impact of purchase transactions', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(231', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'940', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Capitalization of intangible and other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6,967', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(908', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash used in investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(160,291', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(20,427', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Financing activities:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Proceeds from the exercise of warrants and options', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,222', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,881', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Proceeds from the issuance of common stock, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,281', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'83,341', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Borrowings under revolving credit facility', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'77,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Repayments of notes payable and other', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2,475', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(107', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'103,028', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'94,115', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net change in cash, cash equivalents and short-term\ninvestments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(59,248', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'85,013', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash, cash equivalents and short-term investments, beg of\nperiod', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'96,971', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'22,419', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash, cash equivalents short-term investments, end of period', u'\n', u'\xa0', u'\n', u'$', u'\n', u'37,723', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'107,432', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'5\n', u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'3\n', u'w01887martek.gif\n', u'GRAPHIC\n', u'\nbegin 644 w01887martek.gif\nM1TE&.#=A00).`\'(B(B9F9FJJJJ[N[O,\nMS,S=W=WN[N[___\\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!\nM`@,!`@,!`@,!`@,!`@,$__#)26MUS=G-N_]@*(YD:9YHJJYLZ[YP+,]TO2Z*\nMH1=\\?RP:FW!(+!J/R*1RR6P>%81"-,JC2@FZA7/+[7J_X+!XC\'0L#-:>0:K;\nM^;3DN\'Q.K]OO^$EC3258"3\\4#%*$"\'F\'B(F*BXR("SV$A&L)&PB0!\'"-FINAP@U((&@J\\/%JU:N7V\nM]_CY30X&I5=]!*ZA*>`N%34>!UIELU7@@+Z\'$"-*1#\'M2A4IVQA$,Q1RNM;!/5\\)(4\nMA_PNCB3ILZG3IXK66"ST(-O*\'J,*V+2([B(EJ#B@4#]"H6!PJF7HK2N4!?2"#GX@&6"DM5\\YJUXMUP%C5I0/1J$9T,$_4M!Z-`/)NK?O\nMIK:QYDWW%F\'5KA_[3G\'X&TR0YM"]!&]F8(_IV5@;/-K]UI_E*@,', u'```$(1-^_)3AAF1_Q%87_(6@P)*!1(!$`P((,\nM-NB@@\\PI]N"$$Q;&DX(4-J@??QPJX1H/"M##T\'?H:,"08@8JPP(-R!3E8`:D', u'B$1*', u'LRPK"[\nM2;3+H,,0QVR!,]@2PH`JR3UV9@&I30F`G1(`*6/\'TBP8C00#9]CE)BXO"+,0\nM)SL(ILQ47_#/Q+-A$IILJ*KJ+`CB2H"`C%-O0&DF43^8\\B)-`_"T$&V_777,\nMAHX4"9(!$M=5`?\\6^S,%0E,(\\@9ZNDU!TA0NK4G/\\\'84L@\\H0]5[`E`)BE[>#:(6#00`9\'K$[T`XRKL\'K?\'>>365L9#\nM`PR(!,D!OD!1W0C\\3F!Z@P)T7\'BYB$^X>0?R\'7#?A`$(T!`04]XG@/;;3[\\@\nM?&FY7(U+#)1?^(,#F*_^ZRXAL/V#UFO[P', u'/#/8X/SG(Q"UYD\\7`XIUE@#P?P8`X[)8`/YO"#B>I?A[K!\nMDAY', u'\\.EF@$BUJD$\'%"(^P&*J@I@`-2EH\',3**.Z/$8Z\nM5$"0BHZ+X@;:1JP*&"!9#L!37I!&(47:K@.1;%#9*@"K+%K@DA48A--HA\\', u'XQ!+DC\\?[V1!DI,FE`JT#S\'O2\\":SQ=+4#G0?>V*`&X$F%59R0ON0H-Y', u'7)`_XY^?`"%`)5/"JQQ3OX,*0JRJ', u'>"2%E/@!4\'J40M$,6H;,:=$$2!">(@TJ"``:T"\\)+:*R\nMG"(+VN90T>T4!3:=0`CQ0]6JFO"IS\'R05LJ$/J%Z%6P?VZ6,!(G2E(:3!,!H\nM@`+.2!\\YEO4!,O445"V:U"_Y\\`"[V,5=]:I7O%*`F.ZLI"J_VD^B%NU&":QK\nMXD*!@`&L+`"E\\(,', u'V', u'C2/_+8@1OOHTOM=D`+2^J-?I%D`.@!,I&8"EB9)!`B#E.3Y&C$?\'K=/&:U%WM=JB1E-KV"BIYRUO!J_-WDNN][PGRF]^QUO?SX&\'"8.$G_"D[!$#1[4[D#91>>^[X?2>\nM=X%SD\'""$\\"E\'VC`Y=A8/?R`VAH6\\/?#&1QQ?`]9W_LFN;SA[.Z6KZ?8&0;V\nM$M`%\\Q)(VN4XS[G.=\\[SGOO\\YT`/NM"\'_T[THNE)M[K4E:[UIC.]ZU@/^]6S7O6R?_WI5@>[V', u'UL?SO]R_WO??=ZW@=O][YW_?!\\+SSA_7Y7HSO^\\9"/O.0G\nM3_G*6_[RGZ@7-8+@&FT\\&00:`;#Q]@(:!\'!DR)>-6+M=4"\\&[R*C0\\`!YO\'X\nM;0!\\Q1(;3AWK%HG4"L0(\'-\\+V7Q#@/0B("``SZE7$O0R`8/-7HA(^AD&$O#(\nM3&@\'\'-J9AP;&AC;L/8J6#0"/4/\\7A+(_?&PD>O_]"X/]\\P"`ZJ%^X7=!$T"`6S)DXK=^Z`(:P\'!_SP', u'!N;)I\nM>A(`SE)]GC.$0+,E79(E6C`VP/-!WQ\\*0"KQ3$](@:+;D$\'_8&', u'@>0"QI7`-NP!Z6G`PG@DK?(,X5A/58(#@A@@]2F*@H4Q0.1.#X^I2VQ2$$AHRW6\n;H"A(8@G:II!B^04:.)9F*1\'T\\\'EG*0$1```[\n`\nend\n\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']